Research News
Taking a unique approach to better diagnose and treat one of the world’s leading causes of blindness, a researcher from the University of Canberra in Australia has received a $500,000 boost for his three-year project, thanks to a grant from BrightFocus Foundation’s Macular Degeneration Research program.
Izervay, a second drug to treat the advanced and severe form of dry macular degeneration known as geographic atrophy, has received full FDA approval, opening another avenue of hope for people with this vision-stealing condition.
For the first time, a research team has created laboratory-grown cone photoreceptor cells that respond to light, unlocking a potential new way to treat macular degeneration.
A BrightFocus-funded research team has identified how an FDA-approved antioxidant may be used to help prevent age-related macular degeneration in people with certain genetic risk factors for the disease.
Factors that stress the body, such as obesity, can make people more likely to develop macular degeneration when they’re older, even if they’ve returned to a normal weight, new research shows.
A recent study reveals that an anti-inflammatory drug approved to treat certain autoimmune diseases can counteract a protein in the body that’s linked to age-related macular degeneration. These findings may lead to a new treatment option for the disease.
BrightFocus Foundation celebrates the U.S. Food and Drug Administration’s approval of Syfovre (pegcetacoplan injection), the first-ever treatment to slow the progression of vision loss from geographic atrophy, an advanced form of dry age-related macular degeneration and a leading cause of blindness.
The U.S. Food and Drug Administration in November granted Breakthrough Therapy designation for a new treatment that could slow the progression of geographic atrophy, an advanced and severe form of dry age-related macular degeneration that can lead to permanent vision loss.
David Liao, MD, offers insights into managing and understanding AMD and what forthcoming FDA approval could mean for treatment.
If approved, the drug pegcetacoplan would become the first-ever treatment in the U.S. for geographic atrophy, a blinding and advanced form of age-related macular degeneration.
